Condition: Ovarian Cancer · Sponsor: NovoCure Ltd.
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer . The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Arizona Oncology- Biltmore Cancer Center | Phoenix, Arizona, United States | — |
| Arizona Oncology | Tucson, Arizona, United States | — |
| University of California | La Jolla, California, United States | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | — |
| California Pacific Medical Center- Pacific Campus | San Francisco, California, United States | — |
| Olive View - UCLA Medical Center | Sylmar, California, United States | — |
| Rocky Mountain Cancer Centers | Aurora, Colorado, United States | — |
| University of Colorado Denver | Aurora, Colorado, United States | — |
| Rocky Mountain Cancer Centers | Boulder, Colorado, United States | — |
| Rocky Mountain Cancer Centers | Colorado Springs, Colorado, United States | — |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | — |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | — |
+ 107 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03940196